- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02400827
Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors (OVAMAR)
Study About Contamination of Ovarian Tissue by RT-PCR in Children With Solid Tumors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Some solid tumors have high risk of metastatic localization including in ovaries. There is concern over the possible presence of malignant cells in ovarian tissue that could cause a recurrence of the primary disease after reimplantation. Thus, the possibility of ovarian tissue involvement needs to be evaluated with sensitive molecular methods. Those techniques are now available for leukaemia but histology is still the only way for solid tumors.
Based on our experience in detection by RT-PCR of minimal residual disease (MRD) in neuroblastoma since 1994 [Tchirkov et al. 2003] and in ovarian tissue cryopreservation since 1995 [Schubert et al. 2005, Chambon in press], we want to develop a specific and sensitive method for residual disease detection by RT-PCR in order to evaluate the tumor contamination of ovarian harvested tissue.
Study population: We chose 3 models of pediatric solid tumors with high risk of metastases and which often require sterilizing treatments (chemo and/or radiotherapy): neuroblastoma, Ewing tumor and alveolar rhabdosarcoma. We will use four tumor cells lines: IMR32 and SK-NSH for neuroblastoma; RD-ES for Ewing tumor; RH-30 for rhabdosarcoma. We plan to use 20 fragments per line.
Study duration: 12 months Study design: Ovarian tissue without known malignancy but with a condition warranting laparoscopy (benign cysts) will be harvested during kystectomy (perikystic tissue).
The harvested ovarian cortex will be cut: one half will be frozen according to our routine protocol [Schubert et al. 2005] and the other half will be contaminated with tumor cells lines. Then, detection of the specific transcript will be done by RT-PCR in fresh tissue and after freeze/thaw. Total RNA will be extracted with the TRI-reagent and qRT-PCR will be performed using the "TaqMan" technology.
Primary endpoint: to reach a sensitivity about 1/106 cells.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- Recruiting
- CHU de Clermont-Ferrand
-
Principal Investigator:
- Justyna KANOLD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women of any age, diagnosed with a benign cyst that needs a laparoscopy may be included
Exclusion Criteria:
-
Study Plan
How is the study designed?
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
cryopreservation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
malignant cells about 1/10*6 cells.
Time Frame: at day 1
|
at day 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: Justyna KANOLD, University Hospital, Clermont-Ferrand
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHU-0229
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Minimal Residual Disease
-
Nanfang Hospital of Southern Medical UniversityUnknownMinimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell TransplantationChina
-
University of LeicesterActive, not recruitingCancerUnited Kingdom
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)WithdrawnAcute Myeloid Leukemia | Minimal Residual Disease NegativityUnited States
-
Karolinska University HospitalMedical University of Graz; Aarhus University Hospital; Centre Hospitalier Universitaire... and other collaboratorsEnrolling by invitationPancreatic AdenocarcinomaSweden
-
University Hospital, Clermont-FerrandUnknownMinimal Residual Disease | Fertility PreservationFrance
-
AmgenTerminatedMyelodysplastic Syndrome | Relapsed/Refractory AML | Minimal Residual Disease Positive AMLUnited States, Canada, Germany, Netherlands
-
Institute of Hematology & Blood Diseases HospitalRecruiting
-
Guangdong Provincial People's HospitalShenzhen Chipscreen Biosciences Co.LtdRecruitingMinimal Residual Disease | AML, AdultChina
-
Xianmin Song, MDRecruiting
-
Institute of Hematology & Blood Diseases HospitalNot yet recruitingMinimal Residual Disease | Bone Marrow Transplant | Ph+ ALLChina
Clinical Trials on malignant cells
-
University Hospital, Clermont-FerrandUnknownMinimal Residual Disease | Fertility PreservationFrance
-
Oslo University HospitalCompleted
-
Rigshospitalet, DenmarkUniversity of Copenhagen; Technical University of DenmarkRecruitingLymphoma | Head and Neck Cancer | Lymph Node MetastasisDenmark
-
Paolo Giorgio Arcidiacono, MDTerminatedPancreatic Adenocarcinoma | Lymph Node MetastasisItaly
-
Samus Therapeutics, Inc.TerminatedRecurrent Glioblastoma Multiforme (GBM) | Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma | Grade 3 or 4 Astrocytoma | Glioblastoma SurgeryUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingMalignant Fungating WoundChina
-
First People's Hospital of HangzhouCompletedMalignant Biliary ObstructionChina
-
Hospital Universitario La FeUnknownMalignant Hyperthermia | Polymorphisms in Genes RYR1 and CACNAS1SSpain
-
Sun Yat-sen UniversityRecruitingConjunctival Neoplasms | Eye Neoplasms | Orbital NeoplasmsChina
-
Fundació Institut de Recerca de l'Hospital de la...Terminated